Handling HPAPIs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Handling HPAPIs


Pharmaceutical Technology Europe
Volume 22, Issue 9

What facilities, equipment and processes are required when working with HPAPIs and how do these differ from those for traditional APIs?


IMAGES COURTESY OF NOVASEP.
In essence, highly potent active pharmaceutical ingredients (HPAPIs) present a high pharmacological activity at very low doses and thus, raise a number of issues when it comes to their manufacture; the main concern being the occupational hazard associated with their handling. Indeed, because of the substantial toxicity of HPAPIs — especially cytotoxic compounds — the risk of direct contact between the substance and either the operators or an open environment should be eliminated. Consequently, the manufacture of HPAPIs requires highly contained facilities that include different levels of protection. For instance, typical equipment includes isolators and glove boxes while HPAPI plants are isolated from the rest of the facility through negative differential pressure and efficient air treatment. It is worth noting that because of their high potency, HPAPIs are produced at a smaller scale than traditional APIs, with annual commercial production of a cytotoxic compound rarely exceeding 10s to 100s of kilograms, which makes confinement easier to control. Careful attention should also be paid to cleaning, waste management and destruction. For example, equipment should include cleaning in place devices and operators should wear special personal protection equipment adapted to the level of risk associated with the handling of a specific HPAPI. Another important aspect to consider is the set up of specific procedures, controls and practices to ensure that the appropriate level of safety is reached.

In addition to the equipment and procedures, chemical processes and unit operations might be different than with traditional APIs. For instance, product drying will be avoided wherever possible and preparative chromatography is commonly used for purification because HPAPIs are often complex molecules and difficult to purify with crystallisation (low yields). Moreover, chromatography allows safe purification because this technique is fully automated and the confinement of highly active compounds is easily maintained.

How has pharma's increased use of HPAPIs influenced the development of specialised manufacturing equipment?

A large variety of specialised equipment, such as isolators, glove boxes, highly efficient particle air filters, etc. is now available. However, building HPAPI capabilities requires strong experience in the field in order to design the appropriate installations. Thus, specialised manufacturing equipment alone is not sufficient and the plant should be considered as a whole.

What common mistakes, dangers and challenges should companies be aware of when first handling HPAPIs?

Since no general guidelines have been issued for HPAPI manufacturing, this mastery can only be obtained through extensive and long-lasting experience in handling highly potent molecules. We would discourage any company from handling highly potent molecules for the first time without the support of experts in the field. Manufacturing HPAPIs is not only a question of equipment and procedures, but also a question of know-how and commitment to ensure the safe handling of highly potent molecules.

Does the manufacture of HPAPIs present any specific quality control challenges?

Yes. First of all, the majority of analyses have to be performed in-house since HPAPI analysis is not commonly done on a subcontract basis. As a result, HPAPI manufacturers need dedicated equipment for quality control. Because levels of highly potent impurities must be very low, highly effective analytical equipment and measurement methods are absolutely necessary. Lastly, given the risk associated with the handling of HPAPIs, quality control is subjected to the same constraints as R&D and production, and needs to be performed in the appropriate environment (e.g., lab hoods equipped with glove boxes and HEPA filters) and using very specific procedures.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here